Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

528 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system.
Baldini L, Goldaniga M, Guffanti A, Broglia C, Cortelazzo S, Rossi A, Morra E, Colombi M, Callea V, Pogliani E, Ilariucci F, Luminari S, Morel P, Merlini G, Gobbi P. Baldini L, et al. J Clin Oncol. 2005 Jul 20;23(21):4662-8. doi: 10.1200/JCO.2005.06.147. J Clin Oncol. 2005. PMID: 16034042
Prognostic factors in symptomatic Waldenstrom's macroglobulinemia.
Merlini G, Baldini L, Broglia C, Comelli M, Goldaniga M, Palladini G, Deliliers GL, Gobbi PG. Merlini G, et al. Among authors: baldini l. Semin Oncol. 2003 Apr;30(2):211-5. doi: 10.1053/sonc.2003.50064. Semin Oncol. 2003. PMID: 12720138
Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?
Gobbi PG, Baldini L, Broglia C, Goldaniga M, Comelli M, Morel P, Morra E, Cortelazzo S, Bettini R, Merlini G. Gobbi PG, et al. Among authors: baldini l. Clin Cancer Res. 2005 Mar 1;11(5):1786-90. doi: 10.1158/1078-0432.CCR-04-1899. Clin Cancer Res. 2005. PMID: 15756000
Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance.
Rossi F, Petrucci MT, Guffanti A, Marcheselli L, Rossi D, Callea V, Vincenzo F, De Muro M, Baraldi A, Villani O, Musto P, Bacigalupo A, Gaidano G, Avvisati G, Goldaniga M, Depaoli L, Baldini L. Rossi F, et al. Among authors: baldini l. Clin Cancer Res. 2009 Jul 1;15(13):4439-45. doi: 10.1158/1078-0432.CCR-08-3150. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509142
Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias.
Luminari S, Goldaniga M, Ceccherelli F, Guffanti A, Bombardieri E, Marcheselli R, Cro L, Colombi M, Federico M, Baldini L. Luminari S, et al. Among authors: baldini l. Br J Haematol. 2003 Jun;121(5):772-4. doi: 10.1046/j.1365-2141.2003.04353.x. Br J Haematol. 2003. PMID: 12780792 Free article.
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias.
Goldaniga M, Ferrario A, Cortelazzo S, Guffanti A, Pavone E, Ambrosetti A, Marcheselli L, Rossi F, Luminari S, Rossi A, Cro L, Federico M, Lambertenghi Deliliers G, Baldini L. Goldaniga M, et al. Among authors: baldini l. Am J Hematol. 2008 May;83(5):349-54. doi: 10.1002/ajh.21065. Am J Hematol. 2008. PMID: 18186522 Free article.
ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, La Sala A, Merli F, Stelitano C, Pozzi S, Scalone R, Di Renzo N, Musto P, Baldini L, Cervetti G, Angrilli F, Mazza P, Brugiatelli M, Gobbi PG; HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Federico M, et al. Among authors: baldini l. J Clin Oncol. 2009 Feb 10;27(5):805-11. doi: 10.1200/JCO.2008.17.0910. Epub 2009 Jan 5. J Clin Oncol. 2009. PMID: 19124807 Clinical Trial.
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
Chisesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A, Gobbi P, Vitolo U, Stelitano C, Pavone V, Merli F, Liberati M, Baldini L, Bordonaro R, Pesce EA, Federico M. Chisesi T, et al. Among authors: baldini l. J Clin Oncol. 2011 Nov 10;29(32):4227-33. doi: 10.1200/JCO.2010.30.9799. Epub 2011 Oct 11. J Clin Oncol. 2011. PMID: 21990405 Clinical Trial.
Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, Stelitano C, Musso M, Baldini L, Galimberti S, Angrilli F, Polimeno G, Scalzulli PR, Ferrari A, Marcheselli L, Federico M. Merli F, et al. Among authors: baldini l. J Clin Oncol. 2016 Apr 10;34(11):1175-81. doi: 10.1200/JCO.2015.62.4817. Epub 2015 Dec 28. J Clin Oncol. 2016. PMID: 26712220 Free article. Clinical Trial.
528 results